1. Cannabidiol Alleviates Chronic Prostatitis and Chronic Pelvic Pain Syndrome via CB2 Receptor Activation and TRPV1 Desensitization
- Author
-
Jun Jie Piao, Soomin Kim, Dongho Shin, Hwa Jong Lee, Kyung-Hwa Jeon, Wen Jie Tian, Kyung Jae Hur, Jong Soo Kang, Hyun-Je Park, Joo Young Cha, Aeri Song, Sang-Hyuck Park, Mahadevan Rajasekaran, Woong Jin Bae, Sungjoo Kim Yoon, and Sae Woong Kim more...
- Subjects
cannabidiol ,prostatitis ,receptor ,cannabinoid ,cb2 ,toll-like receptor 4 ,trpv1 receptor ,Medicine ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Purpose: This study elucidates the mechanism of the physiological effect of cannabidiol (CBD) by assessing its impact on lipopolysaccharide (LPS)-induced inflammation in RWPE-1 cells and prostatitis-induced by 17β-estradiol and dihydrotestosterone in a rat model, focusing on its therapeutic potential for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Materials and Methods: RWPE-1 cells were stratified in vitro into three groups: (1) controls, (2) cells with LPS-induced inflammation, and (3) cells with LPS-induced inflammation and treated with CBD. Enzyme-linked immunosorbent assays and western blots were performed on cellular components and supernatants after administration of CBD. Five groups of six Sprague– Dawley male rats were assigned: (1) control, (2) CP/CPPS, (3) CP/CPPS and treated with 50 mg/kg CBD, (4) CP/CPPS and treated with 100 mg/kg CBD, and (5) CP/CPPS and treated with 150 mg/kg CBD. Prostatitis was induced through administration of 17β-estradiol and dihydrotestosterone. After four weeks of CBD treatment, a pain index was evaluated, and prostate tissue was collected for subsequent histologic examination and western blot analysis. Results: CBD demonstrated efficacy in vivo for CP/CPPS and in vitro for inflammation. It inhibited the toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) pathway by activating the CB2 receptor, reducing expression of interleukin-6, tumor necrosis factor-alpha, and cyclooxygenase-2 (COX2) (p more...
- Published
- 2025
- Full Text
- View/download PDF